Ticlopidine, an antiplatelet agent, is widely used for the prevention of coronary artery stent thrombosis or for secondary prevention of stroke and transient ischemic attack. Although asymptomatic elevation of liver enzymes has been reported in 5% of patients taking ticlopidine, jaundice due to ticlopidine was rare. We have recently experienced three cases presented with jaundice due to ticlopidine. All three patients developed first symptoms less than 30 days after ticlopidine medication. Their liver function test showed elevation of serum alkaline phosphatase level and hyperbilirubinemia. Histopathologic examination which was performed in two of them showed cholestatic hepatitis. In two patients who have been followed up, jaundice was disappeared 22 and 28 weeks after cessation of the drug, respectively. Thus, in diagnosis of a patient who shows abnormal liver function test of cholestatic pattern while taking ticlopidine for less than one month, we should consider the possibility of ticlopidine induced hepatitis and forbid the patient to take the drug at appropriate time. (Kor J Gastroenterol 2000;36:419 - 423)